A drug, called STA-4783, has been developed to kill cancer cells.
Unlike current treatments, the drug has very few side-effects, and those who have started taking the drug have already doubled their life expectancy, with researchers believing that survival rates could be even higher.
"This is the most exciting cancer treatment I've seen in 10 years," Daily Express quoted cancer specialist Dr Tony Williams of Synta Pharmaceuticals, who is developing the drug, as saying.
STA-4783 works by increasing the amount of free radicals in the body and healthy cells can control these damaging molecules. Cancer cells can't, and react by destroying themselves.
The drug is the first treatment to improve survival rates for patients with late-stage melanoma (skin cancer).
The first trial involved eighty-one patients and those on STA-4783 have survived twice as long as those on old therapies.
Scientists are now looking forward to use the drug to treat ovarian cancer and leukaemia.
Later this year, more trials are to be launched at 150 leading cancer centres across the world, including 11 hospitals in Britain.
And if the outcomes of the trials are as good as the first test, STA-4783 could be available within three years.